The estimated Net Worth of Paul Daruwala is at least $3.27 Million dollars as of 12 September 2022. Mr. Daruwala owns over 16,199 units of Cidara Therapeutics Inc stock worth over $2,569,170 and over the last 9 years he sold CDTX stock worth over $38,400. In addition, he makes $662,422 as Chief Operating Officer at Cidara Therapeutics Inc.
Paul has made over 6 trades of the Cidara Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 16,199 units of CDTX stock worth $11,015 on 12 September 2022.
The largest trade he's ever made was selling 16,199 units of Cidara Therapeutics Inc stock on 12 September 2022 worth over $11,015. On average, Paul trades about 1,970 units every 68 days since 2016. As of 12 September 2022 he still owns at least 221,099 units of Cidara Therapeutics Inc stock.
You can see the complete history of Mr. Daruwala stock trades at the bottom of the page.
Paul Daruwala serves as Chief Operating Officer of the Company. From September 2012 to October 2014 he was the Vice President of the U.S. Viral Hepatitis Franchise (HCV and HBV) at Bristol-Myers Squibb Company, a global pharmaceutical company. Before joining Bristol-Myers Squibb Company, Mr. Daruwala founded Delta Sage, a private consulting practice, in February 2012. From May 2010 to February 2012, Mr. Daruwala served as Vice President of Commercial and Strategic Management for HCV at Vertex Pharmaceuticals Incorporated, a biotechnology company, where he was responsible for the therapeutic area strategy, marketing, patient services, and a national field team of health care provider support. From 1992 to May 2010, Mr. Daruwala served in a number of roles at Merck & Co., a global pharmaceutical company, including: the U.S. lead for HCV, Global Lead for Antiviral New Products, Global Lead for the Hospital Antifungal Franchise, and Director of Marketing and Strategic Planning for the Anti-inflammatory and Analgesic Franchise. Mr. Daruwala spent several years in a business development role, leading commercial and strategic assessments which culminated in preclinical through Phase 2 transactions in oncology, infectious diseases, immunology, and metabolic diseases. He started his career in sales, sales management, and managed markets in Merck’s U.S. division. Mr. Daruwala received his degree in pharmacy from The University of Kentucky.
As the Chief Operating Officer of Cidara Therapeutics Inc, the total compensation of Paul Daruwala at Cidara Therapeutics Inc is $662,422. There are 4 executives at Cidara Therapeutics Inc getting paid more, with Jeffrey Stein having the highest compensation of $1,451,970.
Paul Daruwala is 51, he's been the Chief Operating Officer of Cidara Therapeutics Inc since 2018. There are 10 older and 8 younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
Paul's mailing address filed with the SEC is C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, STE 101, SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio... und Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include: